Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Renal Hemodynamics in T2DM and CKD
NCT06555146Not yet recruiting
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Aug 2024
- Primary completion
- Mar 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of semaglutide in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) (2 arms), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoints: Total Renal Blood Flow at Day 8 and Regional Renal Perfusion at Day 8. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06555146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06555146.